Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: A phase ii randomized, double-blind placebo controlled trial

Journal of the Pancreas

Volumn 13, Issue 5, 2012, Pages 514-518

  Shah, Tilak Upendra ^a   Liddle, Rodger ^a   Stanley Branch, M ^a   Jowell, Paul ^a   Obando, Jorge ^a   Poleski, Martin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aprepitant; Cholangiopancreatography; Endoscopic retrograde; Neurokinin 1; Pancreatitis; Receptors

Indexed keywords

APREPITANT; PLACEBO;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LENGTH OF STAY; MALE; OUTCOME ASSESSMENT; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PANCREATITIS; PILOT PROJECTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866432081     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mallery, J.S., et al., Complications of ERCP. Gastrointest Endosc, 2003. 57(6): p. 633-638.
2. Freeman, M.L., et al., Complications of endoscopic biliary sphincterotomy. N Engl J Med, 1996. 335(13): p. 909-918.
3. Loperfido, S., et al., Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc, 1998. 48(1): p. 1-10.
4. Andriulli, A., et al., Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol, 2007. 102(8): p. 1781-1788.
5. Akashi, R., et al., Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc, 2002. 55(1): p. 50-54.
6. Cheon, Y.K., et al., Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc, 2007. 65(3): p. 385-393.
7. Pezzilli, R., et al., Mechanisms involved in the onset of post- ERCP pancreatitis. JOP, 2002. 3(6): p. 162-168.
8. Raty, S., et al., Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg, 2001. 5(4): p. 339-345; discussion 345.
9. Mazaki, T., H. Masuda, and T. Takayama, Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy, 2010. 42(10): p. 842-853.
10. Singh, P., et al., Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc, 2004. 60(4): p. 544-550.
11. Sofuni, A., et al., Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol, 2007. 5(11): p. 1339-1346.
12. Zheng, M., et al., Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas, 2008. 37(3): p. 247-253.
13. Rabenstein, T., et al., Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc, 2004. 59(6): p. 606-613.
14. Kapetanos, D., et al., A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc, 2007. 66(3): p. 513-518.
15. Bang, U.C., et al., Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther, 2009. 29(10): p. 1078-1085.
16. Chen, B., T. Fan, and C.H. Wang, A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol, 2010. 10: p. 85.
17. Elmunzer, B.J., et al., A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut, 2008. 57(9): p. 1262-1267.
18. Dai, H.F., X.W. Wang, and K. Zhao, Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int, 2009. 8(1): p. 11-16.
19. Tsujino, T., T. Kawabe, and M. Omata, Antiproteases in preventing post-ERCP acute pancreatitis. JOP, 2007. 8(4 Suppl): p. 509-517.
20. Jowell, P.S., et al., Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. Pancreas, 2011. 40(4): p. 533-539.
21. Andriulli, A., et al., Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc, 2007. 65(4): p. 624-632.
22. Nathan, J.D., et al., Capsaicin vanilloid receptor-1 mediates substance P release in experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol, 2001. 281(5): p. G1322-G1328.
23. Nathan, J.D., et al., Primary sensory neurons: a common final pathway for inflammation in experimental pancreatitis in rats. Am J Physiol Gastrointest Liver Physiol, 2002. 283(4): p. G938-G946.
24. Bhatia, M., et al., Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci U S A, 1998. 95(8): p. 4760-4765.
25. Baluk, P., et al., NK1 receptors mediate leukocyte adhesion in neurogenic inflammation in the rat trachea. Am J Physiol, 1995. 268(2 Pt 1): p. L263-L269.
26. He, Z.J., et al., Intraductal administration of an NK1 receptor antagonist attenuates the inflammatory response to retrograde infusion of radiological contrast in rats: implications for the pathogenesis and prevention of ERCP-induced pancreatitis. Pancreas, 2003. 27(1): p. e13-e17.
27. Jin, Y., et al., Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis. Support Care Cancer, 2011.
28. Basch, E., et al., Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2011.
29. Hargreaves, R., et al., Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapyinduced nausea and vomiting. Ann N Y Acad Sci, 2011. 1222: p. 40-48.
30. Cotton, P.B., et al., Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc, 1991. 37(3): p. 383-393.
31. Liddle, R.A. and J.D. Nathan, Neurogenic inflammation and pancreatitis. Pancreatology, 2004. 4(6): p. 551-559; discussion 559-60.
32. Noble, M.D., et al., A pH-sensitive, neurogenic pathway mediates disease severity in a model of post-ERCP pancreatitis. Gut, 2008. 57(11): p. 1566-1571.
33. Shrikhande, S.V., et al., NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain, 2001. 91(3): p. 209-217.